Valneva SE (INRLF)
USD 1.98
(0.0%)
USD 1.98
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 153.71 Million EUR | -57.46% |
| 2022 | 361.3 Million EUR | 3.8% |
| 2021 | 348.08 Million EUR | 215.52% |
| 2020 | 110.32 Million EUR | -12.58% |
| 2019 | 126.19 Million EUR | 11.64% |
| 2018 | 113.03 Million EUR | 7.35% |
| 2017 | 105.29 Million EUR | 11.94% |
| 2016 | 94.06 Million EUR | 20.04% |
| 2015 | 78.35 Million EUR | 112.22% |
| 2014 | 36.92 Million EUR | 21.28% |
| 2013 | 30.44 Million EUR | 787.35% |
| 2012 | 3.43 Million EUR | -66.57% |
| 2011 | 10.26 Million EUR | 22.25% |
| 2010 | 8.39 Million EUR | 171.16% |
| 2009 | 3.09 Million EUR | -9.42% |
| 2008 | 3.41 Million EUR | 294.69% |
| 2007 | 866 Thousand EUR | -62.82% |
| 2006 | 2.32 Million EUR | -22.65% |
| 2005 | 3.01 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 38.06 Million EUR | 16.2% |
| 2024 Q1 | 32.75 Million EUR | -21.83% |
| 2023 Q4 | 41.89 Million EUR | 10.05% |
| 2023 Q2 | 40.23 Million EUR | 20.08% |
| 2023 Q3 | 38.07 Million EUR | -5.38% |
| 2023 FY | 153.71 Million EUR | -57.46% |
| 2023 Q1 | 33.5 Million EUR | -69.92% |
| 2022 Q2 | 71.37 Million EUR | 226.69% |
| 2022 Q1 | 21.84 Million EUR | -92.15% |
| 2022 FY | 361.3 Million EUR | 3.8% |
| 2022 Q4 | 111.4 Million EUR | -28.9% |
| 2022 Q3 | 156.67 Million EUR | 119.51% |
| 2021 Q1 | 23.21 Million EUR | -54.9% |
| 2021 Q2 | 24.28 Million EUR | 4.61% |
| 2021 FY | 348.08 Million EUR | 215.52% |
| 2021 Q4 | 278.23 Million EUR | 1145.13% |
| 2021 Q3 | 22.34 Million EUR | -7.99% |
| 2020 Q2 | 12.68 Million EUR | -63.98% |
| 2020 Q4 | 51.47 Million EUR | 370.46% |
| 2020 FY | 110.32 Million EUR | -12.58% |
| 2020 Q1 | 35.22 Million EUR | -21.39% |
| 2020 Q3 | 10.94 Million EUR | -13.76% |
| 2019 Q2 | 19.65 Million EUR | -43.61% |
| 2019 Q4 | 44.8 Million EUR | 66.65% |
| 2019 FY | 126.19 Million EUR | 11.64% |
| 2019 Q1 | 34.85 Million EUR | 0.43% |
| 2019 Q3 | 26.88 Million EUR | 36.79% |
| 2018 Q1 | 32.08 Million EUR | 10.82% |
| 2018 FY | 113.03 Million EUR | 7.35% |
| 2018 Q4 | 34.7 Million EUR | 79.25% |
| 2018 Q3 | 19.36 Million EUR | -27.98% |
| 2018 Q2 | 26.88 Million EUR | -16.2% |
| 2017 FY | 105.29 Million EUR | 11.94% |
| 2017 Q4 | 28.94 Million EUR | 28.76% |
| 2017 Q2 | 25.41 Million EUR | -10.65% |
| 2017 Q3 | 22.48 Million EUR | -11.54% |
| 2017 Q1 | 28.44 Million EUR | 9.27% |
| 2016 Q1 | 23.74 Million EUR | 13.36% |
| 2016 FY | 94.06 Million EUR | 20.04% |
| 2016 Q4 | 26.03 Million EUR | 41.51% |
| 2016 Q3 | 18.39 Million EUR | -28.95% |
| 2016 Q2 | 25.89 Million EUR | 9.02% |
| 2015 Q2 | 18.59 Million EUR | -0.11% |
| 2015 Q1 | 18.61 Million EUR | 61.92% |
| 2015 FY | 78.35 Million EUR | 112.22% |
| 2015 Q4 | 20.94 Million EUR | 3.68% |
| 2015 Q3 | 20.2 Million EUR | 8.68% |
| 2014 Q4 | 11.49 Million EUR | 3.81% |
| 2014 Q3 | 11.07 Million EUR | 37.16% |
| 2014 Q1 | 6.28 Million EUR | -29.26% |
| 2014 FY | 36.92 Million EUR | 21.28% |
| 2014 Q2 | 8.07 Million EUR | 28.55% |
| 2013 Q2 | 7 Million EUR | 850.47% |
| 2013 Q3 | 13.82 Million EUR | 97.37% |
| 2013 Q1 | 737 Thousand EUR | -17.65% |
| 2013 FY | 30.44 Million EUR | 787.35% |
| 2013 Q4 | 8.87 Million EUR | -35.79% |
| 2012 Q4 | 895 Thousand EUR | -13.28% |
| 2012 Q3 | 1.03 Million EUR | 0.0% |
| 2012 FY | 3.43 Million EUR | -66.57% |
| 2011 FY | 10.26 Million EUR | 22.25% |
| 2010 FY | 8.39 Million EUR | 171.16% |
| 2009 FY | 3.09 Million EUR | -9.42% |
| 2008 FY | 3.41 Million EUR | 294.69% |
| 2007 FY | 866 Thousand EUR | -62.82% |
| 2006 FY | 2.32 Million EUR | -22.65% |
| 2005 FY | 3.01 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -874.526% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -872222.797% |
| SQZ Biotechnologies Company | 21.47 Million USD | -615.672% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -743.737% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -25.016% |
| Mesoblast Limited | 5.9 Million USD | -2504.405% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Genus plc | 668.8 Million USD | 77.017% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -37375.65% |
| Marizyme, Inc. | 645.81 Thousand USD | -23701.428% |
| ContraFect Corporation | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -200147.522% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -233760.759% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -388867.053% |
| MultiCell Technologies, Inc. | 49.32 USD | -311662511.517% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -209.149% |
| EV Biologics, Inc. | 48.9 Thousand USD | -314239.468% |
| Q BioMed Inc. | 284.35 Thousand USD | -53956.944% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -419.35% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 37.341% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -219488.571% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -155174.057% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -202889.805% |
| IMV Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -23242.749% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 98.954% |
| Halberd Corporation | 999.00 USD | -15386486.587% |
| Enzolytics Inc. | 52.79 Thousand USD | -291043.268% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -11128.05% |
| SYBLEU INC | 11.69 Thousand USD | -1314127.086% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -25159.767% |
| argenx SE | 1.22 Billion USD | 87.466% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -7856.108% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -24797.309% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 81.691% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -5.935% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -27461.277% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -15306.234% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -217.889% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -821.236% |
| ONE Bio Corp. | 52.29 Million USD | -193.926% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -64878.018% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -64878.018% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -109504.826% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -32347.175% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -1873.45% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1182300.0% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -388709.632% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -4515.976% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -2206.257% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -14694.225% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -496.546% |
| CSL Limited | 14.8 Billion USD | 98.961% |
| Cellectis S.A. | 755 Thousand USD | -20259.205% |